Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

A Randomized, Double-blind, Active-controlled, Multicenter phase 3 Clinical trial to evaluate the Efficacy and Safety of Concomitant Mometasone furoate and Levocabastine HCl in Perennial Allergic Rhinitis patients

Inclusion criteria

• male, female, Age: over 13 years(no age limiation in upper)
• subject who has experienced perennial allergic rhinitis for over 1 year
• subject who has identified allergens throughout the year within 12 months
• subject who has the symptoms of moderate to severe allergic rhinitis
• subject who can record the the patient diary during the clinical trial period
• subject who agreed to keep the same environment during the clinical trial period

Exclusion criteria

• Asthma
• Previous medical history at screening (Nasal polyps within the previous two months, biopsies, ulcers, trauma, surgery, atrophic rhinitis, patients with a history of drug rhinitis)
• Patients with untreated localized infection in nasal mucosa
• Patients following administration of a combination of prohibited drugs in patients administered concomitant medications or trial period is expected to be inevitable
• Patients with abnormal following laboratory test results at screening

• AST, ALT>2times the upper limit of normal at screening
• Serum creatinine >1.5times the upper limit of normal at screening
• Previous history of acute or severe chronic sinusitis within 30 days at screening
• The continue use of drugs that may affect the efficacy of the Investigational product
• Start the immunotherapy or a change of doge within 1 month, at screening
• If you have glaucoma or cataracts, herpes simplex, or around the eyes
• Chronic obstructive pulmonary disease (COPD)
• history of hypersensitivity reactions and for treaties or major components of the IP
• Pregnant women, breast feeding women or women of childbearing potential must agree to use appropriate contraception methods
• Alcohol or illegal drug abuse or dependence in patients
• participation in any investigational or maketed drug within 4weeks preceding the screening visit
• Patients that can not be participating in a clinical trial by investigator's discretion